Phase III Study of BAY 43-9006 in Patients With Advanced Hepatocellular Carcinoma Treated After Transcatheter Arterial Chemoembolization (TACE).

Trial Profile

Phase III Study of BAY 43-9006 in Patients With Advanced Hepatocellular Carcinoma Treated After Transcatheter Arterial Chemoembolization (TACE).

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2013

At a glance

  • Drugs Sorafenib (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Bayer
  • Most Recent Events

    • 09 Jun 2011 Results published in the European Journal of Cancer.
    • 22 Nov 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
    • 24 Jan 2010 Primary endpoint 'Time to disease recurrence' has not been met. No significant difference was found between sorafenib and placebo recipients in the central review. Results presented at ASCO 2010 Gastrointestinal Cancers Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top